Divi's Laboratories Ltd
NSE:DIVISLAB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 367.85
6 214.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Divi's Laboratories Ltd
Divi's Laboratories Ltd
Current Portion of Long-Term Debt
Divi's Laboratories Ltd
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Current Portion of Long-Term Debt
₹10m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Suven Life Sciences Ltd
NSE:SUVEN
|
Current Portion of Long-Term Debt
₹2.4m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dishman Carbogen Amcis Ltd
NSE:DCAL
|
Current Portion of Long-Term Debt
₹17.8B
|
CAGR 3-Years
213%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Syngene International Ltd
NSE:SYNGENE
|
Current Portion of Long-Term Debt
₹1.1B
|
CAGR 3-Years
93%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
|
Tarsons Products Ltd
NSE:TARSONS
|
Current Portion of Long-Term Debt
₹24.9m
|
CAGR 3-Years
839%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
Innova Captab Ltd
NSE:INNOVACAP
|
Current Portion of Long-Term Debt
₹107.4m
|
CAGR 3-Years
23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Divi's Laboratories Ltd
Glance View
Divi's Laboratories Ltd. is a prominent player in the pharmaceutical industry, primarily known for its role as a leading manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Founded in 1990, the company has established a robust reputation for its high-quality products and commitment to research and development. With an extensive product portfolio that serves a multitude of therapeutic areas, including pain management, oncology, and cardiovascular treatments, Divi's has positioned itself as a trusted partner to both domestic and global pharmaceutical companies. The company's state-of-the-art manufacturing facilities, compliant with international regulatory standards, ensure that it meets the growing demand for cost-effective and high-quality APIs, which is increasingly vital as the world turns to generics and specialty medicines. For investors, Divi's Laboratories presents a compelling opportunity anchored in its sustainable growth trajectory and financial resilience. Over the years, the company has demonstrated strong revenue growth and healthy profit margins, reflecting its operational efficiency and strategic focus on innovation. With a diversified customer base across more than 95 countries, the company is well-positioned to capitalize on emerging market trends and the ongoing expansion in global healthcare requirements. As healthcare systems evolve and the demand for affordable pharmaceuticals surges, Divi’s commitment to excellence and innovation keeps it at the forefront of the industry, making it an attractive investment for those looking to align with a company that not only generates value but also significantly contributes to global health outcomes.
See Also
What is Divi's Laboratories Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
10m
INR
Based on the financial report for Jun 30, 2024, Divi's Laboratories Ltd's Current Portion of Long-Term Debt amounts to 10m INR.
What is Divi's Laboratories Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
8%
Over the last year, the Current Portion of Long-Term Debt growth was 104%. The average annual Current Portion of Long-Term Debt growth rates for Divi's Laboratories Ltd have been 8% over the past three years .
You don't have any saved screeners yet
